Flourish Research ("Flourish" or the "Company"), an NMS Capital portfolio company and leading multi-site clinical trial ...

Moderate coffee or caffeine consumption may lower the risk of developing multiple cardiometabolic diseases, according to ...

The latest study should be a comfort for caffeine drinkers, but isn't necessarily a sign to start a new habit.

Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human ...

Despite this, there is a paucity of research examining the impact of these ... multi-phase explanatory study (REB 2023-8964) ...

Mahableshwarkar M.D., DLFAPA, Senior Vice President, Clinical Development ... decades of pharmaceutical industry experience in new drug development across all phases of research (pre-IND to ...

FineHeart S.A, a clinical-stage medtech company developing breakthrough solutions for cardiology, is pleased to announce the appointment of André-Jacques Auberton-Hervé to its Board of Directors. This ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...